HL Science Co Ltd

HL Science Co Ltd has a market price of 8,930 KRW and a market cap of 45.48 billion KRW, with a price-to-book ratio of 0.55 and a price-to-tangible-book ratio of 0.55, indicating a significant discount to book value. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. However, the company reported negative operating and free cash flows of -7.05 billion KRW and -9.82 billion KRW, respectively, indicating liquidity constraints. The current ratio of 15.63 suggests strong short-term liquidity, but the negative cash flows raise concerns about the sustainability of operations. The company's return on equity (ROE) is -14.43%, and return on assets (ROA) is -14.01%, both significantly below the industry median for Food Processing, which typically sees positive returns. The negative profitability metrics suggest operational inefficiencies or declining demand for its products. Gross profit of 8.56 billion KRW is insufficient to cover operating expenses, leading to an operating loss of 13.24 billion KRW and a net loss of 11.92 billion KRW. HL Science Co Ltd's revenue of 16.71 billion KRW is derived from health functional foods, over-the-counter drugs, health-oriented foods, genetic analysis services, and home beauty devices. The company does not disclose segment-specific revenue, but the concentration of revenue in a few product lines increases exposure to market volatility. The geographic exposure is primarily domestic, with no significant international revenue disclosed, which limits diversification benefits. The company's growth trajectory is uncertain, with no outlook data provided for the current or next fiscal year. The negative operating and free cash flows suggest a lack of growth momentum, and the absence of capital expenditures indicates a potential pause in expansion or innovation. The company's recent financial performance, including a net loss and negative cash flows, raises concerns about its ability to sustain operations and invest in future growth. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the negative cash flows and operating losses suggest potential liquidity constraints in the near term. The company has no long-term debt, which reduces financial risk, but the lack of capital expenditures and negative cash flows may indicate a lack of investment in growth opportunities. The dilution risk is low, but the company's financial performance may necessitate future equity issuance to fund operations. Recent events, including the latest financial filing, show a continuation of negative financial performance. The company has not disclosed any significant events or strategic initiatives that could reverse its current trajectory. The absence of recent positive developments or strategic announcements suggests a lack of momentum in the business.